P53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: A case-control study

Molecular Biology Reports

Volumn 39, Issue 2, 2012, Pages 1639-1647

  Sümbül, Ahmet Taner ^a,b   Akkız, Hikmet ^a   Bayram, Süleyman ^c   Bekar, Aynur ^a   Akgöllü, Ersin ^a   Sandıkçı, MacIt ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Case control study; Genetic susceptibility; Hepatocellular carcinoma; P53 Arg72Pro polymorphism

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS B VIRUS; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; P53 GENE; PHENOTYPE; PROTEIN DOMAIN; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TUMOR SUPPRESSOR GENE; TURKEY (REPUBLIC); GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; RISK FACTOR;

HEPATITIS B VIRUS;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TURKEY;

EID: 84860292713     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0903-2     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. doi:10.3322/canjclin.55.2.74 (Pubitemid 40372904)
2. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma path-ogenesis: from genes to environment. Nat Rev Cancer 6:674-687. doi:10.1038/nrc1934 (Pubitemid 44286000)
3. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576. doi:10.1053/j.gastro. 2007.04.061 (Pubitemid 46890874)
4. Jin S, Levine AJ (2001) The p53 functional circuit. J Cell Sci 114:4139-4140 (Pubitemid 33138651)
5. Levine AJ (1997) P53, the cellular gatekeeper for growth and division. Cell 88:323-331. doi:10.1016/S0092-8674(00)81871-1 (Pubitemid 27131374)
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53. doi: 10.1126/science.1905840 (Pubitemid 21917115)
7. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878 (Pubitemid 24289415)
8. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC (2003) TP53 and liver carcinogenesis. Hum Mutat 21:201-216. doi: 10.1002/humu.10176 (Pubitemid 36292963)
9. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963 (Pubitemid 17004567)
10. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP (1988) A variation in the structure of the protein-coding region of the human p53 gene. Gene 70:245-252. doi: 10.1016/0378-1119(88)90196-5
11. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93:15335-15340 (Pubitemid 27009601)
12. Shepherd T, Tolbert D, Benedetti J, Macdonald J, Stemmermann G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C (2000) Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118:1039-1044 (Pubitemid 30346980)
13. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887-898 (Pubitemid 27399550)
14. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matla-shewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100 (Pubitemid 29046852)
15. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650-4656 (Pubitemid 17217402)
16. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365. doi:10.1038/ng1093 (Pubitemid 36278852)
17. Pim D, Banks L (2004) p53 polymorphism variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199. doi:10.1002/ijc.11548 (Pubitemid 37541770)
18. Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is aff ected by the codon 72 polymorphism. Oncogene 25:3489-3500. doi:10.1038/sj.onc.1209405 (Pubitemid 43901670)
19. Murphy ME (2006) Polymorphic variants in the p53 pathway. Cell Death Differ 13:916-920. doi:10.1038/sj.cdd.4401907
20. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, New-meyer DD, Schuler M, Green DR (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014. doi:10.1126/science. 1092734 (Pubitemid 38209704)
21. Leu JI, Dumont P, Hafey M, Murphy ME, George DL (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6:443-450. doi:10.1038/ncb1123 (Pubitemid 38607505)
22. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95-107. doi:10.1038/nrc2584
23. Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, de Pancorbo MM (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193:199-205. doi:10.1016/S0304-3835(03) 00046-6 (Pubitemid 36428903)
24. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, De Silvestri A, Silini EM (2004) Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 208:75-79. doi:10.1016/j.canlet.2004.02.016 (Pubitemid 38501786)
25. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, Hu Z (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128:412-417. doi:10.1002/ijc.25342
26. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC (2005) Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 11:289-292 (Pubitemid 40125222)
27. Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, Gao B, Hou LF, Zhu GS (2005) A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 229:77-83. doi: 10.1016/j.canlet.2005.04.014 (Pubitemid 41262542)
28. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, Hassar M, Pineau P, Benjelloun S (2007) The Pro variant of the p53 codon 72 polymorphism is associated with hepato-cellular carcinoma in Moroccan population. Hepatol Res 37:748-754. doi:10.1111/j.1872-034X.2007.00126.x (Pubitemid 47054781)
29. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim do Y, Chon CY, Han KH (2008) MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29:1192-1196. doi:10.1093/car cin/bgn090 (Pubitemid 351964880)
30. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ (1999) A p53 genetic polymorphism as a modulator of hepato-cellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29:697-702. doi:10.1002/hep.510290330
31. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ü lger Y (2011) Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem 347:201-208. doi: 10.1007/s11010-010-0629-9
32. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ozdil B (2010) Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J Viral Hepat 17:668-674. doi:10.1111/j.1365-2893.2009.01225.x
33. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430 (Pubitemid 32844200)
34. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH (1994) Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 14:98-102
35. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the esophagus for bleeding esophageal varices. Br J Surg 60:646-649
36. Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC (2001) Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61:8718-8722 (Pubitemid 34013882)
37. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5:845-856. doi:10.1038/nrc1739 (Pubitemid 41746029)
38. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999) Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 35:226-230. doi:10.1016/S0959-8049 (98)00369-4
39. Shen H, Solari A, Wang X, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wei Q (2004) P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 11:1115-1120
40. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Manto-vani F, Breuer J, Leigh IM, Matlashewski G, Banks (1998) Role of a p53 polymorphism in the development of human papillo-mavirus-associated cancer. Nature 393:229-234. doi:10.1038/30400 (Pubitemid 28261713)
41. 0 M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C (2003) Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9:4860-4864 (Pubitemid 37323290)
42. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Saïd S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764-770. doi:10.1196/annals.1299.137 (Pubitemid 38265078)
43. Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, Beckman L (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44:266-270 (Pubitemid 24229554)
44. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15:583-587. doi:10.1093/carcin/15.4.583 (Pubitemid 24124397)
45. Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26:1317-1323. doi:10.1038/sj.onc.1210199 (Pubitemid 46328460)
46. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121-124. doi:10.1126/science. 1140485 (Pubitemid 47056470)